Fluvoxamine
 Fluvoxamine(SSRI, drug)   | |
|---|---|
| An SSRI |
Fluvoxamine may be of use in treating long Covid.
Effects
Fluvoxamine can cross the blood-brain barrier.
In 2021, amid the COVID-19 pandemic, several U.S. universities began clinical trials evaluating the effectiveness of fluvoxamine in mitigating the more severe symptoms of coronavirus disease 2019. Researchers reported that administering fluvoxamine prevented inflammation of the lungs in COVID-19 patients.[1]
A double-blind controlled study found that fluvoxamine may prevent clinical deterioration in outpatients with symptomatic COVID-19. The study had important limitations: it was run fully remotely; it had a small sample size (150) and short follow-up duration (15 days).[2] The accompanying editorial noted that, although this study is important enough to choose out of more than 10,000 other COVID-19 related submissions, it "presents only preliminary information [and] the findings should be interpreted as only hypothesis generating; they should not be used as the basis for current treatment decisions."[3] Similarly, the study authors themselves cautioned that "the trial's results should not be treated as a measure of fluvoxamine's effectiveness against COVID-19 but as an encouraging indicator that the drug warrants further testing."[4] A prospective open-labelled cohort study showed similar results.[5]
References
- ↑ "Common Anti-Depressant Pill Shows Promise In Fighting COVID-19". NBC 6 South Florida. Retrieved 2021-02-04.Page Module:Citation/CS1/styles.css must have content model "Sanitized CSS" for TemplateStyles (current model is "Scribunto").
- ↑ Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, Miller JP, Yang L, Yingling M, Avidan MS, Reiersen AM (December 2020). "Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial". JAMA. 324 (22): 2292–2300. doi:10.1001/jama.2020.22760. PMID 33180097 Check
|pmid=value (help).Page Module:Citation/CS1/styles.css must have content model "Sanitized CSS" for TemplateStyles (current model is "Scribunto"). - ↑ Seymour CW, Bauchner H, Golub RM (December 2020). "COVID-19 Infection-Preventing Clinical Deterioration". JAMA. 324 (22): 2300. doi:10.1001/jama.2020.21720. PMID 33180115 Check
|pmid=value (help).Page Module:Citation/CS1/styles.css must have content model "Sanitized CSS" for TemplateStyles (current model is "Scribunto"). - ↑ University of Virginia Health System (November 14, 2020). "Antidepressant Fluvoxamine May Prevent COVID-19 Infections From Worsening". SciTechDaily.Page Module:Citation/CS1/styles.css must have content model "Sanitized CSS" for TemplateStyles (current model is "Scribunto").
- ↑ Seftel, David; Boulware, David R (February 2021). "Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19". Open Forum Infectious Diseases. Oxford University Press. 8 (2). doi:10.1093/ofid/ofab050. ISSN 2328-8957.Page Module:Citation/CS1/styles.css must have content model "Sanitized CSS" for TemplateStyles (current model is "Scribunto").
